Flagship Biosciences

Flagship Biosciences' Services

Flagship Biosciences offers a comprehensive suite of discovery, translational, and clinical testing services. With a focus on oncology, immune-oncology, neuromuscular disorders, and cell and gene therapies for rare diseases, the company provides advanced assay development services. Their capabilities extend to genomic analysis, including full genome sequencing, RNA sequencing, spatial transcriptomics, and methylation sequencing. This broad range of services positions Flagship Biosciences as a pivotal player in the biopharmaceutical and healthcare industries, aiding in the development and validation of therapeutic interventions.

Flagship Biosciences' Digital Pathology and Image Analysis

Flagship Biosciences has developed a cutting-edge digital pathology and image analysis department, powered by its proprietary artificial intelligence software, Flotilla. This AI-driven platform delivers customized deep-learning solutions for digital pathology and image analysis, enhancing the accuracy and efficiency of diagnostics. The department also offers multiplex IHC, FISH, and CISH assays capable of detecting up to six biomarkers per sample. With seventeen US patents backing its proprietary image analysis technology, Flagship Biosciences stands out in the field of digital pathology, providing precise and reliable diagnostic solutions.

Flagship Biosciences' Genomic and Spatial Profiling Technologies

Utilizing state-of-the-art technologies, Flagship Biosciences delivers comprehensive genomic and spatial profiling services. The company partners with Genomenon® to access an extensive rare disease and oncology genetics library and employs NanoString’s GeoMx® Digital Spatial Profiler for highly multiplexed tissue profiling. Their Next Generation Sequencing capabilities, powered by Illumina® systems like NovaSeq™ 6000 and NovaSeq™ X Plus, enable high-capacity sequencing. Additionally, the NanoString nCounter® Pro Analysis System allows for multiplexing up to 800 targets in gene expression studies, making Flagship Biosciences a leader in advanced genomic research.

Flagship Biosciences' Flow Cytometry and Custom Panel Services

Flagship Biosciences provides extensive flow cytometry assessments that support applications in hematopoietic neoplasms, minimal residual disease (MRD), receptor occupancy, expansive immunophenotyping, and immuno-oncology. Their CLIA-validated test panels support comprehensive work-ups on lymphoid and myeloid malignancies. Additionally, the company utilizes the Luminex FLEXMAP 3D® system to create custom panels capable of tracking up to 500 analytes in a single sample. With an extensive library of validated singleplex, duplex, and multiplex panels, Flagship Biosciences offers tailored solutions to meet the specific needs of their clients.

Flagship Biosciences' Regulatory Expertise and FDA Collaboration

Flagship Biosciences has a proven track record of collaborating directly with the FDA to ensure therapeutic success. Their consultative approach to data science integrates results from spatial proteomic and genomic data, providing comprehensive insights that support regulatory submissions. By working closely with regulatory bodies, Flagship Biosciences helps clients navigate the complex landscape of therapeutic development, ensuring that their products meet the stringent requirements necessary for approval. This expertise underscores the company's commitment to advancing healthcare through innovative and compliant solutions.